Britain and America have announced a landmark bilateral deal that will guarantee zero duties on UK pharmaceutical exports going into the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has agreed to boost expenditure on pharmaceuticals through the public health system. This move guarantees that import taxes on these key products will remain at zero for a timeframe of the next three years.
This deal comes after earlier threats to hike duties on branded pharmaceutical imports, with increases floated reaching double the cost.
"This arrangement between the United Kingdom bolsters the worldwide climate for new treatments and brings much-needed balance to transatlantic medicine commerce," an announcement noted.
Trade Importance
Medicines are one of the Britain's most significant exports to the US, which is by far the primary buyer for leading British pharmaceutical firms.
Export figures indicate that in the one-year period leading up to last September, the UK sold drugs valued at over eleven billion pounds to the US. This figure made up a significant portion of total UK exports in that span.
"This guarantee secures work, boosts capital expenditure and paves the way for the UK to become a global hub for biotech and pharma," a minister stated.
Specific UK Commitments
The deal entails several key changes from the UK:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it deems new medicines to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a goal to raise overall NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Rebate Cap: The amount pharmaceutical firms must pay back to the NHS to control costs will be limited at fifteen percent. In the past, rebates were more than 20%.
Industry Background
The deal follows a protracted row between the pharmaceutical industry and the ministers over drug pricing and regulatory access.
These tensions were intensified by arguments that American consumers were charged a premium for the same drugs than people in the other developed nations.
Over the last 18 months, several major drug company projects in the UK have been halted or cancelled, while substantial investments have been announced toward American operations.
The Science Minister acknowledged that the NHS must invest a greater share on treatments, noting that its spending on drugs had shrunk as a share of its resources over the previous ten-year period.
